High Purity Muscle Building Peptides Tesamorelin 2mg / vial 218949-48-5
Détail rapide:
Nom du produit: Tésamoréline
Autre nom: usan; Egrifta
CAS: 218949-48-5
MF: C211H366N72O67S1
MW: 5135.89
Apparence: poudre blanche
Pureté (HPLC): 99.3%
Masse moléculaire:5135.89
Apparence:poudre blanche
Emballage :According to every customer’s requirement.
Catrgory :Polypeptides Hormone
Tesamorelin Application:
1. Tesamorelin is a new AIDS Drug Bodybuilders Take for Fat Loss
There are a wide variety of drugs that can help bodybuilders achieve major muscle gains and cut fat quickly and efficiently. But despite the large number of drugs already out there, new things that can help bodybuilders. And one of the latest potential bodybuilding drugs is EGRIFTA the brand name of the drug tesamorelin.
2. Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
3. Tesamorelin Boosts Cognition in Elderly
A peptide that increases growth hormone release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, also reported greater subjective improvement in cognition relative to the placebo group.
Tesamorelin Boosts Cognition in Elderly
Tesamorelin is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
A peptide that increases growth hormone release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, a researcher said here. Scores on standard tests of executive function and verbal memory were significantly higher in participants given tesamorelin (Egrifta), a synthetic analog of growth hormone releasing hormone (GHRH), in a 20-week trial, according to Laura D. Baker, PhD.. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.
In animal studies, GHRH administration improved biomarkers of brain function as well as performance on cognition tests. And a 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairment were randomized to placebo or tesamorelin at 1 mg/day subcutaneously.
Directeur commercial